Moderate to severe Hemophilia B patients
Hemophilia B is an inherited bleeding disorder caused by factor IX deficiency. Disease severity and inhibitor status influence management and therapeutic decisions.
Biomarkers used in this indication
Each approval combines this indication with specific biomarker criteria and a therapy. Select a therapy from the tables below to open its FDA-defined testing pathway.
Defined explicitly for Moderate to severe Hemophilia B patients in FDA labeling.
| Biomarker | Biomarker criteria | Therapies |
|---|---|---|
| AAV Antibodies |
|
Defined at the solid tumor level and applicable to Moderate to severe Hemophilia B patients and other solid tumor cancers.
No tumor-agnostic biomarker approvals are currently mapped for this indication.
Therapies with biomarker-defined approvals
Each therapy below has at least one FDA companion diagnostic approval tied to Moderate to severe Hemophilia B patients. Select a therapy to view the specific approval and eligible tests.
AAV Antibodies (serotype rh74)